Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
News Jan 24, 2008
Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces that it has achieved another targeted milestone in its Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd.
Dalton Medicinal Chemistry Partners is utilizing its medicinal chemistry expertise to design and synthesize novel compounds against an antiviral target selected by Boehringer Ingelheim (Canada) Ltd.
Peter Pekos, President of Dalton Pharma Services, said: "We are pleased to achieve this additional milestone in our exciting partnership with Boehringer Ingelheim (Canada) Ltd. It is a pleasure working with the talented team at BI."
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE